Prohost Letter #401
SYNOPSIS
PART 1 In this Letter
CONTENTS
Duchenne Muscular Dystrophy (DMD)
FDA Compassionate Approval of Eteplirsen!
PART 2
In The Letter Issue #402
CONTENTS
EYE ON IONIS (IONS)
Antisense Proof of Concept and Feasibility
EYE ON INVIVA (INVA) AND THERAVANCE BIOPHARMA (TBPH)
Sales of The Ellipta Inhalers Started to Pick up Before an expected Boom
Not Losing . . .
This content is for paid subscribers.
Prohost Letters
November 16, 2016